ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical (CLSD), Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...
Recently published Wet AMD Market Insights report includes a comprehensive understanding of current treatment practices, wet ...
A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...
– The vast majority of patients on the “go-forward” regimen had no inflammation and >90% of patients have no or minimal inflammation (0 or 0.5+ AC cells) – – Preliminary efficacy and safety data ...
Adverum Biotechnologies' gene therapy for wet age-related macular degeneration (AMD) reduced treatment burden and maintained visual acuity in a phase 2 study, though a full picture can't be formed yet ...
An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results